

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Eli Lilly and Company

Action Requested: Authorization to amend an Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form.

This proposed agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Dr. Marschall Runge is an employee of the University of Michigan (“University”), and a paid member of the Board of Directors of Eli Lilly and Company. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Marschall Runge, MD, PhD, the Executive Vice President for Medical Affairs and Dean of the Medical School, is a paid member of the Board of Directors of the for-profit company called Eli Lilly and Company (the “Company”). The Company wishes to amend a research agreement previously approved by the Regents on October 15, 2015 to include the proposal entitled, “The Renal Pre-Competitive Consortium (RPC2 – Eli Lilly (2017))” (ORSP #17-PAF04035) in the Department of Internal Medicine under the direction of Dr. Matthias Kretzler. The purpose of this amendment is to continue efforts in the Consortium to facilitate pre-competitive renal research by providing access and analysis of a number of large datasets associated with renal disease to better understand key pathways and identify potential targets for the development of diagnostic and therapeutic compounds. Dr. Runge is not involved in any manner in this research project and was not involved in any manner in the negotiation of the Agreement terms.

Agreement Terms:

The terms of the Amendment conform to University policy. The period of performance for the project is extended to December 31, 2017. The amount of additional funding support will not exceed \$269,619. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement

The Amendment will provide continued support of an effort by Dr. Kretzler to use his expertise and University laboratory, as well as other University resources to work collaboratively with the Consortium member to identify biological targets that may be used to develop new and novel diagnostic and therapeutic compounds.

Recommendations:

Dr. Runge has properly disclosed his service to the Company pursuant to the regular conflict of interest process and policies that apply to Executive Officers of the University: The president has put in place a management plan for this conflict which calls for Dr. Runge to recuse himself from any University decisions involving a business relationship with the Company and to inform the president when he is required to do so. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Eli Lilly and Company.

Respectfully submitted,



S. Jack Hu
Vice President for Research

February 2017